Premium
Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses
Author(s) -
Burkett Bren.,
Thomason John M.,
Hurdle Holly M.,
Wills Robert W.,
Fontenot Robin L.
Publication year - 2016
Publication title -
veterinary surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.652
H-Index - 79
eISSN - 1532-950X
pISSN - 0161-3499
DOI - 10.1111/vsu.12567
Subject(s) - medicine , phenylbutazone , pharmacology , thromboxane , thromboxane b2 , anesthesia , platelet aggregation , platelet
Objective Determine the effects of nonsteroidal anti‐inflammatory drugs (NSAID) on platelet function and thromboxane synthesis immediately after drug administration and following 5 days of NSAID administration in healthy horses. Study Design Randomized cross‐over study. Animals Healthy adult horses (n=9; 6 geldings and 3 mares). Methods Horses received either flunixin meglumine (1.1 mg/kg IV every 12 hours), phenylbutazone (2.2 mg/kg IV every 12 hours), or firocoxib (loading dose of 0.27 mg/kg IV on day 1, then 0.09 mg/kg IV every 24 hours for 4 days) for a total of 5 days. Blood samples were collected prior to drug administration (day 0), 1 hour after initial NSAID administration (day 1), and then 1 hour post‐NSAID administration on day 5. Platelet function was assessed using turbidimetric aggregometry and a platelet function analyzer. Serum thromboxane B 2 concentrations were determined by commercial ELISA kit. A minimum 14 day washout period occurred between trials. Results At 1 hour and 5 days postadministration of firocoxib, flunixin meglumine, or phenylbutazone, there was no significant effect on platelet aggregation or function using turbidimetric aggregometry or a platelet function analyzer. There was, however, a significant decrease in thromboxane synthesis at 1 hour and 5 days postadministration of flunixin meglumine and phenylbutazone that was not seen with firocoxib. Conclusion Preoperative administration of flunixin meglumine, phenylbutazone, or firocoxib should not inhibit platelet function based on our model. The clinical implications of decreased thromboxane B 2 synthesis following flunixin meglumine and phenylbutazone administration are undetermined.